Federal health regulators announced Thursday they have granted full approval to a Boehringer Ingelberg medication targeting patients battling advanced lung cancer who have already undergone previous treatments.
The Food and Drug Administration’s decision represents just the second drug to receive clearance through the agency’s Commissioner’s National Priority Voucher pilot program, a special pathway designed to expedite certain treatments.
The approval provides a new treatment option for patients facing this challenging form of cancer who have exhausted other therapeutic approaches.
